share_log

和黃醫藥：和黃醫藥宣佈主席退任、委任新主席及董事委員會成員變動

HUTCHMED: HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees

Hong Kong Stock Exchange ·  May 17 10:00
Summary by Moomoo AI
和黃醫藥（HUTCHMED）今日宣布，杜志強先生在服務公司23年後將退任主席及執行董事職務。公司同時宣布，自2016年起擔任非執行董事的艾樂德博士將接任新主席。艾樂德博士在生物科技、醫療保健等領域擁有超過30年的全球業務領導經驗。杜志強先生表示，他的退任是為了處理私人事務和照顧健康，並將擔任公司策略顧問，繼續為公司作出貢獻。艾樂德博士的任命將於2024年5月17日生效。和黃醫藥是一家專注於發現、開發和商業化治療癌症和免疫性疾病的靶向藥物和免疫療法的生物醫藥公司。
和黃醫藥（HUTCHMED）今日宣布，杜志強先生在服務公司23年後將退任主席及執行董事職務。公司同時宣布，自2016年起擔任非執行董事的艾樂德博士將接任新主席。艾樂德博士在生物科技、醫療保健等領域擁有超過30年的全球業務領導經驗。杜志強先生表示，他的退任是為了處理私人事務和照顧健康，並將擔任公司策略顧問，繼續為公司作出貢獻。艾樂德博士的任命將於2024年5月17日生效。和黃醫藥是一家專注於發現、開發和商業化治療癌症和免疫性疾病的靶向藥物和免疫療法的生物醫藥公司。
HUTCHMED ANNOUNCED TODAY THAT MR. TU CHI KEUNG WILL RETIRE AS CHAIRMAN AND EXECUTIVE DIRECTOR AFTER 23 YEARS AT THE SERVICE COMPANY. THE COMPANY ALSO ANNOUNCED THAT DR. ELDER, WHO HAS BEEN A NON-EXECUTIVE DIRECTOR SINCE 2016, WILL TAKE OVER AS THE NEW CHAIRMAN. Dr. Elder has more than 30 years of global business leadership experience in biotech, healthcare, and more. Mr Tu Chi Keung said his retirement was to deal with private affairs and health care and would continue to contribute to the company as a strategic consultant to the company. Dr. Elder's appointment will take effect on May 17, 2024. WONG PHARMACEUTICALS IS A BIOMEDICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT AND COMMERCIALIZATION OF TARGETED DRUGS AND IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES.
HUTCHMED ANNOUNCED TODAY THAT MR. TU CHI KEUNG WILL RETIRE AS CHAIRMAN AND EXECUTIVE DIRECTOR AFTER 23 YEARS AT THE SERVICE COMPANY. THE COMPANY ALSO ANNOUNCED THAT DR. ELDER, WHO HAS BEEN A NON-EXECUTIVE DIRECTOR SINCE 2016, WILL TAKE OVER AS THE NEW CHAIRMAN. Dr. Elder has more than 30 years of global business leadership experience in biotech, healthcare, and more. Mr Tu Chi Keung said his retirement was to deal with private affairs and health care and would continue to contribute to the company as a strategic consultant to the company. Dr. Elder's appointment will take effect on May 17, 2024. WONG PHARMACEUTICALS IS A BIOMEDICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT AND COMMERCIALIZATION OF TARGETED DRUGS AND IMMUNOTHERAPIES FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more